
Multiple Sclerosis
Latest News
Advertisement
CME Content
Advertisement





















We estimated the long-term risks and benefits of disease modifying therapies. Benefits were favored by natalizumab with minimal increased risks in the negative anti-JC virus population.

In an educational symposium entitled, "The Evolution of Multiple Sclerosis Treatment: The Role of the Managed Care Pharmacist," Kristen Helms, PharmD, and her 2 colleagues discuss how treatments for multiple sclerosis (MS) have evolved over the past 2 decades, explore the novel and emerging therapeutic strategies for MS, and cover strategies to improve medication adherence for the chronic disease.



Advertisement
Advertisement
Trending on AJMC
1
After Narrow Miss in Phase 3 Study, IO Biotech Ponders Next Steps for Immune-Modulatory, Off-the-Shelf Cancer Vaccine
2
Ongoing COVID-19 Circulation Linked to Increases in Health-Related Work Absences, Workforce Exits
3
3 New Study Findings to Look Out for at Menopause Society 2025
4
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
5